Novo Nordisk (NVO) Stock Surges as FDA Approves Oral Wegovy Weight-Loss Pill

TLDR

• FDA approved Novo Nordisk’s oral Wegovy pill on Monday, causing shares to rally 9.5% in after-hours trading
• The 25 mg oral semaglutide tablet is the first oral GLP-1 medication approved for weight management in the United States
• Trial data showed patients lost 16.6% of body weight over 64 weeks versus 2.7% on placebo
• Launch scheduled for early January 2026, giving Novo Nordisk a lead over competitor Eli Lilly in oral obesity treatments
• The approval comes as Novo Nordisk stock has fallen 44% this year due to competition and slowing injectable Wegovy sales

Novo Nordisk stock climbed 9.5% in extended trading Monday following FDA approval of its oral Wegovy weight-loss pill. The Danish pharmaceutical company received clearance for once-daily oral semaglutide 25 mg tablets.

Novo Nordisk A/S, NVO

The approval represents the first oral GLP-1 receptor agonist therapy for weight management approved in the U.S. Novo Nordisk plans to bring the pill to market in early January 2026.

The pill uses the same active ingredient found in injectable Wegovy and Ozempic. Novo Nordisk currently markets an oral semaglutide product called Rybelsus for type 2 diabetes patients.

Strong Clinical Performance

The FDA approved the pill based on results from a 64-week late-stage clinical trial. Participants taking 25 mg of oral semaglutide daily lost an average of 16.6% of their body weight.

Patients on placebo lost only 2.7% of their body weight during the same timeframe. The medication also received approval for reducing the risk of major cardiovascular events.

The pill is approved for chronic weight management in adults with obesity or overweight who have at least one weight-related health condition. This expands access for patients who prefer oral medications over injections.

Novo Nordisk submitted the oral pill for approval to the European Medicines Agency and other international regulators during the second half of 2025.

Market Competition Heats Up

The approval positions Novo Nordisk ahead of rival Eli Lilly in delivering an oral obesity medication to patients. Lilly is developing orforglipron, its own oral weight-loss drug candidate.

Eli Lilly currently dominates the weight-loss injection market with Zepbound. The drug has proven more effective than Novo Nordisk’s injectable Wegovy in head-to-head comparisons.

The global GLP-1 market is projected to reach $100 billion by 2030. Some analysts forecast the broader obesity treatment market could hit $150 billion annually within the next decade.

Novo Nordisk stock has declined 44% year-to-date. The company has issued profit warnings and experienced slowing injectable Wegovy sales due to pressure from Eli Lilly and compounded medication versions.

The oral format could attract millions of new patients who avoid injectable treatments. Many people prefer pills due to convenience or discomfort with needles.

Wall Street analysts maintain a Moderate Buy consensus rating on Novo Nordisk. The rating consists of four Buy recommendations, four Hold ratings, and one Sell rating.

The average analyst price target sits at $55.26 per share. This implies approximately 15% upside potential from current trading levels.

The company will launch the oral Wegovy pill in the United States in early January 2026.

The post Novo Nordisk (NVO) Stock Surges as FDA Approves Oral Wegovy Weight-Loss Pill appeared first on Blockonomi.